Brief: Chugai Obtains Approval Of FoundationOne CDx Cancer Genomic Profile As A Companion Diagnostic For Rozlytrek
27/06/2019 17:23
June 27 (Reuters) - Chugai Pharmaceutical Co Ltd 4519.T :
* CHUGAI PHARMACEUTICAL - CHUGAI OBTAINS APPROVAL OF
FOUNDATIONONE
CDX CANCER GENOMIC PROFILE AS A COMPANION DIAGNOSTIC FOR
ROZLYTREK
Source text for Eikon: ID:nNDL48fG5m
Further company coverage: 4519.T ROG.S
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chugai Pharmaceutical
See all newsRegarding Discontinuation Of Development Of Gym329 (Emugrobart) For Obesity, Return Of License And Resumption Of Development For SMA
Table: Chugai Pharm 6-MTH group results (IFRS)
Japan's Nikkei roars past 62,000 on earnings, Middle East optimism; JGBs rally (updated)
Japan's Nikkei surges past 61,000 for first time on earnings, Mideast optimism
Japan's Nikkei closes above 60,000 for first time on earnings optimism (updated)